Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series

We reported on five people with MS, using immunodepleting disease modifying treatments (anti-CD20 monoclonal antibodies and sphingosine-one-phosphate modulators) and with reduced COVID-19 vaccine response, who had mild-to-moderate symptomatic COVID-19, and were treated with anti-SARS-CoV-2 monoclona...

Descripción completa

Detalles Bibliográficos
Autores principales: Moccia, Marcello, Buonomo, Antonio Riccardo, Scotto, Riccardo, Viceconte, Giulio, Nobile, Mariano, Lanzillo, Roberta, Brescia Morra, Vincenzo, Gentile, Ivan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Clinical Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159779/
https://www.ncbi.nlm.nih.gov/pubmed/35689866
http://dx.doi.org/10.1016/j.jns.2022.120306
_version_ 1784719127921819648
author Moccia, Marcello
Buonomo, Antonio Riccardo
Scotto, Riccardo
Viceconte, Giulio
Nobile, Mariano
Lanzillo, Roberta
Brescia Morra, Vincenzo
Gentile, Ivan
author_facet Moccia, Marcello
Buonomo, Antonio Riccardo
Scotto, Riccardo
Viceconte, Giulio
Nobile, Mariano
Lanzillo, Roberta
Brescia Morra, Vincenzo
Gentile, Ivan
author_sort Moccia, Marcello
collection PubMed
description We reported on five people with MS, using immunodepleting disease modifying treatments (anti-CD20 monoclonal antibodies and sphingosine-one-phosphate modulators) and with reduced COVID-19 vaccine response, who had mild-to-moderate symptomatic COVID-19, and were treated with anti-SARS-CoV-2 monoclonal antibodies. In particular, we showed the possibility to use monoclonal antibodies to speed-up recovery from COVID-19 in MS, in the absence of any COVID-19 residuals or MS changes (e.g., relapses or disability).
format Online
Article
Text
id pubmed-9159779
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-91597792022-06-02 Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series Moccia, Marcello Buonomo, Antonio Riccardo Scotto, Riccardo Viceconte, Giulio Nobile, Mariano Lanzillo, Roberta Brescia Morra, Vincenzo Gentile, Ivan J Neurol Sci Clinical Short Communication We reported on five people with MS, using immunodepleting disease modifying treatments (anti-CD20 monoclonal antibodies and sphingosine-one-phosphate modulators) and with reduced COVID-19 vaccine response, who had mild-to-moderate symptomatic COVID-19, and were treated with anti-SARS-CoV-2 monoclonal antibodies. In particular, we showed the possibility to use monoclonal antibodies to speed-up recovery from COVID-19 in MS, in the absence of any COVID-19 residuals or MS changes (e.g., relapses or disability). Elsevier B.V. 2022-08-15 2022-06-02 /pmc/articles/PMC9159779/ /pubmed/35689866 http://dx.doi.org/10.1016/j.jns.2022.120306 Text en © 2022 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Clinical Short Communication
Moccia, Marcello
Buonomo, Antonio Riccardo
Scotto, Riccardo
Viceconte, Giulio
Nobile, Mariano
Lanzillo, Roberta
Brescia Morra, Vincenzo
Gentile, Ivan
Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series
title Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series
title_full Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series
title_fullStr Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series
title_full_unstemmed Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series
title_short Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series
title_sort monoclonal antibodies for mild-to-moderate covid-19 in multiple sclerosis: a case series
topic Clinical Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159779/
https://www.ncbi.nlm.nih.gov/pubmed/35689866
http://dx.doi.org/10.1016/j.jns.2022.120306
work_keys_str_mv AT mocciamarcello monoclonalantibodiesformildtomoderatecovid19inmultiplesclerosisacaseseries
AT buonomoantonioriccardo monoclonalantibodiesformildtomoderatecovid19inmultiplesclerosisacaseseries
AT scottoriccardo monoclonalantibodiesformildtomoderatecovid19inmultiplesclerosisacaseseries
AT vicecontegiulio monoclonalantibodiesformildtomoderatecovid19inmultiplesclerosisacaseseries
AT nobilemariano monoclonalantibodiesformildtomoderatecovid19inmultiplesclerosisacaseseries
AT lanzilloroberta monoclonalantibodiesformildtomoderatecovid19inmultiplesclerosisacaseseries
AT bresciamorravincenzo monoclonalantibodiesformildtomoderatecovid19inmultiplesclerosisacaseseries
AT gentileivan monoclonalantibodiesformildtomoderatecovid19inmultiplesclerosisacaseseries
AT monoclonalantibodiesformildtomoderatecovid19inmultiplesclerosisacaseseries

Ejemplares similares